Feb 26 (Reuters) - Madrigal Pharmaceuticals Inc MDGL.O:
MADRIGAL ANNOUNCES NEW TWO-YEAR DATA FROM THE COMPENSATED MASH CIRRHOSIS ARM OF THE MAESTRO-NAFLD-1 TRIAL DEMONSTRATING POTENTIAL BENEFIT OF REZDIFFRA™ (RESMETIROM) IN PATIENTS WITH COMPENSATED MASH CIRRHOSIS
MADRIGAL PHARMACEUTICALS INC - REPORTS POSITIVE TWO-YEAR RESULTS FROM PHASE 3 TRIAL
MADRIGAL PHARMACEUTICALS INC - SAFETY PROFILE OF REZDIFFRA CONSISTENT WITH OTHER TRIALS
Source text: ID:nGNXbShBP0
Further company coverage: MDGL.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.